Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer in Patients Treated with Neoadjuvant Chemotherapy
Throughout treatment, KRAS ctDNA is detectable by ddPCR in patients with localized PDAC treated with NAC. Detection of mutant KRAS G12V after resection was associated with reduced OS.
Authors
- Qiang Zhang
- M.C. Cox (ORCID: https://orcid.org/0000-0002-9260-1799)
- John Abad
- Arlene D’Souza
- Robert Bayer
- Amy Wells (ORCID: https://orcid.org/0000-0003-2167-2183)
- Lucas Santana‐Santos (ORCID: https://orcid.org/0000-0002-0872-5431)
- Akhil Chawla (ORCID: https://orcid.org/0000-0003-3122-6873)
- Dominic Vitello (ORCID: https://orcid.org/0000-0002-4163-7759)
- Massimo Cristofanilli (ORCID: https://orcid.org/0000-0002-4194-7175)
- Kevin Dawravoo
- Grace Suh
- Dhavan V. Shah (ORCID: https://orcid.org/0000-0001-5034-2816)
- Yingzhe Liu (ORCID: https://orcid.org/0000-0003-4150-1111)
- Lawrence J. Jennings (ORCID: https://orcid.org/0000-0001-8669-7774)
- Hui Zhang (ORCID: https://orcid.org/0000-0001-7434-7806)
- Lauren M. Janczewski (ORCID: https://orcid.org/0000-0003-2721-3519)
- Larissa Masnyk
- David J. Bentrem
Institutions
- Northwestern University (US)
- Cornell University (US)
- Northwestern Medicine (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- Annals of Surgery
- Published
- 2024-10-14
- DOI
- https://doi.org/10.1097/sla.0000000000006562
- Citations
- 13
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 3.71